2025年国内外肺移植基础研究年度盘点

Annual review of basic research on lung transplantation worldwide in 2025

摘要

肺移植是终末期肺病的确定性治疗手段，可显著改善患者预后。但感染、排斥反应、缺血-再灌注损伤及慢性移植肺功能障碍等术后并发症相互交织，形成复杂的病理网络，对患者长期生存构成持续挑战。2025年度国内外科研团队在肺移植基础研究领域取得系统性进展，通过融合单细胞多组学、空间转录组学及新型动物模型等前沿技术，在感染耐药演化、免疫调控分子机制、程序性细胞死亡、供肺保护策略优化及慢性移植物功能障碍早期预警等方面实现重要突破。本文将系统梳理2025年度国内外肺移植基础研究的代表性进展，深度剖析机制性突破对优化诊疗策略的启示，以期为肺移植基础研究的创新突破与临床转化锚定方向。

Abstract

Lung transplantation is a definitive treatment for end-stage lung disease and can significantly improve patient prognosis. However, postoperative complications such as infection, rejection, ischemia-reperfusion injury and chronic lung allograft dysfunction intertwine to form a complex pathological network, posing persistent challenges to long-term patient survival. In 2025, research teams worldwide have made systematic progress in the field of basic lung transplantation research. By integrating cutting-edge technologies including single-cell multi-omics, spatial transcriptomics and novel animal models, significant breakthroughs have been achieved in the evolutionary dynamics of drug-resistant infections, molecular mechanisms of immune regulation, programmed cell death, optimization of donor lung protection strategies and early warning of chronic lung allograft dysfunction. This article systematically reviews the representative advances in basic lung transplantation research worldwide in 2025, and deeply analyzes the implications of mechanistic breakthroughs for optimizing diagnosis and treatment strategies, aiming to anchor the direction for innovative breakthroughs and clinical translation in basic lung transplantation research.

关键词

肺移植 / 感染 / 排斥反应 / 缺血-再灌注损伤 / 慢性移植肺功能障碍 / 供肺保护

Key words

Lung transplantation / Infection / Rejection / Ischemia-reperfusion injury / Chronic lung allograft dysfunction / Donor lung protection

参考文献

[1] CHRISTIE J D, VAN RAEMDONCK D, FISHER A J. Lung transplantation[J]. N Engl J Med, 2024, 391(19): 1822-1836. DOI: 10.1056/nejmra2401039.

[2] YAMAMOTO A, FUJII N, SEIKE K, et al. Spatial transcriptomics analysis of macrophage-to-myofibroblast transition in bronchiolitis obliterans following hematopoietic stem cell transplantation[J]. Transplant Cell Ther, 2026, 32(4): 454-465. DOI: 10.1016/j.jtct.2025.12.950.

[3] YAN Y, KAIHOU T, LECUONA E, et al. Single-cell dissection of chronic lung allograft dysfunction reveals convergent and distinct fibrotic mechanisms[J]. JCI Insight, 2025, 10(20): e197579. DOI: 10.1172/jci.insight.197579.

[4] JOEAN O, WELTE T, GOTTLIEB J. Chest infections after lung transplantation[J]. Chest, 2022, 161(4): 937-948. DOI: 10.1016/j.chest.2021.10.014.

[5] HINZE C A, SIMON S, GOTTLIEB J. Respiratory infections in lung transplant recipients[J]. Curr Opin Infect Dis, 2025, 38(2): 150-160. DOI: 10.1097/QCO.0000000000001097.

[6] GAO H, WANG B, LI M, et al. Emergence and dissemination of multidrug-resistant Klebsiella pneumoniae harboring the novel tmexCD-toprJ RND efflux pump operon[J]. Front Cell Infect Microbiol, 2025, 15: 1579880. DOI: 10.3389/fcimb.2025.1579880.

[7] ZHANG Y, LI Z, SHI H, et al. High-level ceftazidime-avibactam resistance by in-host evolution of bla(KPC) genes: emergence of a novel bla(KPC-102) variant and increase of bla(KPC-33) copy number in Klebsiella pneumoniae strains from a lung transplantation recipient[J]. Int J Antimicrob Agents, 2025, 66(2): 107521. DOI: 10.1016/j.ijantimicag.2025.107521.

[8] FOX V, VRENNA G, ROSSITTO M, et al. Killing two birds with one stone: emergence of colistin and cefiderocol resistance in a mucoid MDR Acinetobacter baumannii under colistin pressure[J]. Front Microbiol, 2025, 16: 1650028. DOI: 10.3389/fmicb.2025.1650028.

[9] LIAO F, ZHOU D, CANO M, et al. Pseudomonas aeruginosa infection induces intragraft lymphocytotoxicity that triggers lung transplant antibody-mediated rejection[J]. Sci Transl Med, 2025, 17(784): eadp1349. DOI: 10.1126/scitranslmed.adp1349.

[10] HORSTEN F, CHOU S, GILLEMOT S, et al. Dynamics and evolution of donor-derived cytomegalovirus infection in 3 solid organ transplant recipients with the same multiorgan donor[J]. Transplantation, 2025, 109(5): 890-899. DOI: 10.1097/TP.0000000000005209.

[11] MATTHAIOU E I, ALI ABD EL-HAFEEZ A, SHARIFI H, et al. Macrophage ferroptosis inhibits Aspergillus conidial killing in lung transplantation[PP/OL]. bioRxiv(2025-03-15) [2026-03-01]. https://doi.org/10.1101/2025.03.13.643092.

[12] HAVLIN J, SKOTNICOVA A, DVORACKOVA E, et al. Respiratory syncytial virus prefusion F3 vaccine in lung transplant recipients elicits CD4⁺ T cell response in all vaccinees [J]. Am J Transplant, 2025, 25(7): 1452-1460. DOI: 10.1016/j.ajt.2025.03.025.

[13] LIU L, LIN H, CHEN J, et al. Pharmacological EZH2 inhibition attenuates post-transplant obliterative bronchiolitis by reprogramming macrophage polarization[J]. Biochem Pharmacol, 2025, 242(Pt 4): 117419. DOI: 10.1016/j.bcp.2025.117419.

[14] DACCARETT-BOJANINI W N, SOLLMANN M, YARNOFF K M, et al. The role of macrophages in the mitigation by decitabine of acute allograft rejection[J]. Front Transplant, 2025, 4: 1723396. DOI: 10.3389/frtra.2025.1723396.

[15] KHAN M A, LAU C L, KRUPNICK A S. Monitoring regulatory T cells as a prognostic marker in lung transplantation[J]. Front Immunol, 2023, 14: 1235889. DOI: 10.3389/fimmu.2023.1235889.

[16] DE ARAÚJO CASTRO Í, TERADA Y, YOKOYAMA Y, et al. Tolerogenic lung allograft microenvironment suppresses pathogenic tissue remodeling following respiratory virus infection in mice[J]. Am J Transplant, 2025, 25(12): 2515-2528. DOI: 10.1016/j.ajt.2025.08.021.

[17] LI W, TERADA Y, BAI Y Z, et al. Maintenance of graft tissue-resident Foxp3⁺ cells is necessary for lung transplant tolerance in mice [J]. J Clin Invest, 2025, 135(10): e178975. DOI: 10.1172/JCI178975.

[18] JIAO W, LONG K D, YOUNG T, et al. Immunogenomic landscape of T cell repertoires after human lung transplantation and its clinical significance[J]. Am J Transplant, 2025, 25(8): S63. DOI: 10.1016/j.ajt.2025.07.121.

[19] BELIOS I, ZHANG T, URBSCHAT C, et al. Sex hormones regulate the sexual dimorphism of the lung resident immune milieu[J]. Sci Rep, 2025, 15(1): 32032. DOI: 10.1038/s41598-025-15941-6.

[20] TAHMASBPOUR E, PHILP A, CREE T, et al. Proteomic analysis of transbronchial biopsy tissue reveals a distinct proteome and mechanistic pathways in high-grade eosinophilic inflammation after lung transplantation[J]. Transpl Int, 2025, 38: 14080. DOI: 10.3389/ti.2025.14080.

[21] NASROLLAHI-SHIRAZI S, UNTERWURZACHER M, BEREZHINSKIY H O, et al. Serum proteomics analysis of lung transplant patients receiving different induction therapies[J]. Front Immunol, 2025, 16: 1616781. DOI: 10.3389/fimmu.2025.1616781.

[22] KULKARNI H S, TAGUE L K, CALABRESE D R, et al. Impaired complement regulation drives chronic lung allograft dysfunction after lung transplantation[J]. J Clin Investig, 2026, 136: e188891. DOI: 10.1172/jci188891.

[23] XIA T, HOU Z, WANG S, et al. HMGA1 drives EMT in obliterative bronchiolitis through epigenetic regulation of chromatin accessibility in pulmonary epithelial cells[J]. Clin Epigenetics, 2025, 17(1): 192. DOI: 10.1186/s13148-025-02000-0.

[24] CHARYA A V, JANG M K, KONG H, et al. Donor-derived cell-free DNA is associated with the degree of immunosuppression in lung transplantation[J]. Am J Transplant, 2025, 25(9): 1906-1915. DOI: 10.1016/j.ajt.2025.04.011.

[25] ZAJACOVA A, ALKHOURI M, GUNEY M, et al. Exploring acute cellular rejection in lung transplantation: insights from donor-derived cell-free DNA analysis[J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2026, 170(1): 33-39. DOI: 10.5507/bp.2025.016.

[26] YAVUZ G, WALTER J, HIRV K, et al. Donor-derived cell-free DNA for detection of acute rejection in lung transplant recipients[J]. Front Immunol, 2025, 16: 1531774. DOI: 10.3389/fimmu.2025.1531774.

[27] ALNABABTEH M, KELLER M B, KONG H, et al. Early post-transplant recipient tissue injury predicts allograft function, rejection, and survival in lung transplant recipients, evidence from cell-free DNA[J]. Eur Respir J, 2025: 2402537. DOI: 10.1183/13993003.02537-2024.

[28] KORUTLA L, BAI Y Z, DEMARAIS N, et al. B-cell extracellular vesicle biomarkers for detection of antibody-mediated rejection in lung transplantation[J]. JTCVS Tech, 2025, 31: 224-232. DOI: 10.1016/j.xjtc.2025.03.005.

[29] RAVICHANDRAN R, RAHMAN M, BANSAL S, et al. Reduced levels of liver kinase B1 in small extracellular vesicles as a predictor for chronic lung allograft dysfunction in cystic fibrosis lung transplant recipients[J]. Hum Immunol, 2025, 86(1): 111187. DOI: 10.1016/j.humimm.2024.111187.

[30] IBÁÑEZ S A, SANCHEZ C A, GIL P U. BALF lymphocyte and cytokine profiling as biomarkers of acute rejection after lung transplantation[J]. J Pers Med, 2025, 15(7): 267. DOI: 10.3390/jpm15070267.

[31] KAHAN R, ALDERETE I S, GAO Q, et al. Adeno-associated virus-mediated transduction of PD-L1 in a rodent lung transplant model[J]. Am J Transplant, 2025, 25(10): 2082-2089. DOI: 10.1016/j.ajt.2025.05.029.

[32] YARNOFF K M, DACCARETT-BOJANINI W N, VILLABONA-RUEDA A F, et al. Hypomethylating therapy mitigates acute allograft rejection in a murine lung transplant model[J]. Front Transplant, 2025, 4: 1612523. DOI: 10.3389/frtra.2025.1612523.

[33] TAKAHAGI A, MIYAMOTO E, LAM C, et al. Permissive immunosuppression facilitates the expansion of ex vivo administered regulatory T cells in the lung allograft[J]. Sci Rep, 2025, 15(1): 22897. DOI: 10.1038/s41598-025-06835-8.

[34] SCHWARTZ-CORNIL I, PASCALE F, JOUNEAU L, et al. Preconditioning donors with corticosteroids improves early lung graft immunity[J]. Front Immunol, 2025, 16: 1668591. DOI: 10.3389/fimmu.2025.1668591.

[35] ZHUANG H, SONG X, LI J, et al. EMAP-II from macrophage-derived extracellular vesicles drives neutrophil extracellular traps formation via PI3K/AKT/mtROS in lung ischemia/reperfusion injury[J]. Redox Biol, 2025, 85: 103750. DOI: 10.1016/j.redox.2025.103750.

[36] KUBO Y, SUGIMOTO S, OUSAKA D, et al. Histidine-rich glycoprotein ameliorated lung ischemia-reperfusion injury in a mouse model[J]. JHLT Open, 2026, 11: 100453. DOI: 10.1016/j.jhlto.2025.100453.

[37] KAWANA S, OKAZAKI M, SAKAUE T, et al. Loss of Nr4a1 ameliorates endothelial cell injury and vascular leakage in lung transplantation from circulatory-death donor[J]. J Heart Lung Transplant, 2025, 44(2): 249-260. DOI: 10.1016/j.healun.2024.09.028.

[38] GODA Y, TAKAHASHI M, YUASA I, et al. Pharmacological inhibition of toll-like receptor 4 suppresses ischemia-reperfusion injury-induced inflammation and improves lung allograft function after transplantation[J]. JHLT Open, 2025, 10: 100399. DOI: 10.1016/j.jhlto.2025.100399.

[39] WU J, GAO P, YANG C, et al. Targeting mitochondrial complex I of CD177⁺ neutrophils alleviates lung ischemia-reperfusion injury [J]. Cell Rep Med, 2025, 6(5): 102140. DOI: 10.1016/j.xcrm.2025.102140.

[40] KOLLARETH D J M, LEROY V, TU Z, et al. LipoxinA₄/FPR2 Signaling mitigates ferroptosis of alveolar epithelial cells via NRF2-dependent pathway during lung ischemia-reperfusion injury [J]. FASEB J, 2025, 39(8): e70545. DOI: 10.1096/fj.202401475r.

[41] DENG P, WU Y, WAN L, et al. Maresin1 alleviates ischemia reperfusion injury after lung transplantation by inhibiting ferroptosis via the PKA-hippo-YAP signaling pathway[J]. Biomedicines, 2025, 13(7): 1594. DOI: 10.3390/biomedicines13071594.

[42] LIU H, WANG Z, QIU T, et al. Dexmedetomidine alleviates lung ischemia-reperfusion injury by inhibiting cuproptosis: an in vivo study[J]. Front Pharmacol, 2025, 16: 1562535. DOI: 10.3389/fphar.2025.1562535.

[43] ZHAO Y, LIANG L, JEON J E, et al. Ischemia/reperfusion upregulates genes related to PANoptosis in human lung transplants[J]. Transplantation, 2025, 109(6): 1004-1015. DOI: 10.1097/TP.0000000000005268.

[44] GAO X, TANG M, LI J, et al. Activation of Nrf2 pathway by 4-Octyl itaconate enhances donor lung function in cold preservation settings[J]. Respir Res, 2025, 26(1): 69. DOI: 10.1186/s12931-025-03151-7.

[45] WANG D D, XU B, SUN J J, et al. MOTS-c mimics remote ischemic preconditioning in protecting against lung ischemia-reperfusion injury by alleviating endothelial barrier dysfunction[J]. Free Radic Biol Med, 2025, 229: 127-138. DOI: 10.1016/j.freeradbiomed.2025.01.016.

[46] ZHU G, LI Q, YAO Q, et al. β-Nicotinamide mononucleotide activates the SIRT1/NF-κB pathway to alleviate ischemia reperfusion injury after lung transplantation[J]. J Transl Med, 2025, 23(1): 1349. DOI: 10.1186/s12967-025-07382-6.

[47] YANG X, HONG S, YAN T, et al. miR-146a engineered extracellular vesicles derived from mesenchymal stromal cells more potently attenuate ischaemia-reperfusion injury in lung transplantation[J]. Clin Transl Med, 2025, 15(4): e70298. DOI: 10.1002/ctm2.70298.

[48] ZHANG P, QIAO Z, ZHAO S, et al. Characteristics linking ischemia-reperfusion to chronic lung allograft dysfunction in lung transplantation: a single-cell bioinformatics analysis[J]. Transpl Immunol, 2025, 93: 102326. DOI: 10.1016/j.trim.2025.102326.

[49] YANG Z C, LU W Y, GENG Z Y, et al. Identification and validation of biomarkers related to mitochondria during ex vivo lung perfusion for lung transplants based on machine learning algorithm[J]. Gene, 2025, 936: 149097. DOI: 10.1016/j.gene.2024.149097.

[50] GAO J, JIANG X, ZHANG Z, et al. Integrative analysis of scRNA-seq and bulk RNA-seq to identify lactylation-related gene signatures in lung ischemia-reperfusion injury after lung transplantation[J]. Int Immunopharmacol, 2025, 165: 115361. DOI: 10.1016/j.intimp.2025.115361.

[51] ZHUANG F, NING Y, LI C, et al. Single-cell RNA sequencing of pig lung transplantation reveals macrophage ferroptosis in lung ischemia-reperfusion injury[J]. J Heart Lung Transplant, 2025, 44(9): 1516-1520. DOI: 10.1016/j.healun.2025.04.011.

[52] TIAN D, ZHENG X Y, HOU S L, et al. Baicalein relieves lung graft ischemia-reperfusion injury by reducing advanced glycation endproducts: from screens to mechanisms[J]. J Heart Lung Transplant, 2025, 44(6): 932-947. DOI: 10.1016/j.healun.2025.01.023.

[53] TIAN D, HUANG H, WEN H Y. Noninvasive methods for detection of chronic lung allograft dysfunction in lung transplantation[J]. Transplant Rev, 2020, 34(3): 100547. DOI: 10.1016/j.trre.2020.100547.

[54] BRUGIÈRE O, DREYFUSS D, GUILET R, et al. Circulating vesicular-bound HLA-G as noninvasive predictive biomarker of CLAD after lung transplantation[J]. Transplantation, 2025, 109(4): 736-745. DOI: 10.1097/TP.0000000000005175.

[55] VOSOUGHI D, ULAHANNAN A, LI Q, et al. Humoral immunity to lung antigens early post-transplant confers risk for chronic lung allograft dysfunction[J]. J Heart Lung Transplant, 2025, 44(7): 1109-1119. DOI: 10.1016/j.healun.2025.02.1577.

[56] VAN DER PLOEG E A, FAIZ A, TEITSMA G J, et al. It takes two: aberrant repair and low-grade inflammation characterize bronchiolitis obliterans syndrome after lung transplantation in serum proteomic analysis[J]. JHLT Open, 2025, 9: 100303. DOI: 10.1016/j.jhlto.2025.100303.

[57] PICKERING H, ARAKAWA-HOYT J, LLAMAS M, et al. Cytomegalovirus-associated CD57⁺ KLRG1⁺ CD8⁺ TEMRA T cells are associated with reduced risk of CMV viremia in kidney transplantation and chronic allograft dysfunction in lung transplantation [J]. Hum Immunol, 2025, 86(3): 111285. DOI: 10.1016/j.humimm.2025.111285.

[58] WEIGT S S, ZHOU J, OKUNO T, et al. Development and validation of a bronchoalveolar lavage genomic classifier for acute cellular rejection[J]. EBioMedicine, 2025, 122: 106046. DOI: 10.1016/j.ebiom.2025.106046.

[59] KUHNERT S, ROTERT A M, SOMMERLAD J, et al. Increase in alveolar septal width is a histological predictor of chronic lung allograft dysfunction and survival in lung transplant recipients-a longitudinal study[J]. J Clin Med, 2025, 14(18): 6368. DOI: 10.3390/jcm14186368.

[60] TAHMASBPOUR E, PHILP A, SIVASUBRAMANIAM V, et al. Proteomic analysis of transbronchial biopsies to discover novel biomarkers for early identification of chronic lung allograft dysfunction[J]. Transplant Direct, 2025, 11(6): e1800. DOI: 10.1097/TXD.0000000000001800.

[61] TANAKA S, TANIMINE N, NAKAKURA A, et al. Activation of anti-donor CD8 alloimmune response in clinically diagnosed acute rejection early after living-donor lobar lung transplantation and its impact on outcome[J]. Transpl Immunol, 2025, 90: 102201. DOI: 10.1016/j.trim.2025.102201.

[62] BOS S, HUNTER B, MCDONALD D, et al. High-dimensional tissue profiling of immune cell responses in chronic lung allograft dysfunction[J]. J Heart Lung Transplant, 2025, 44(4): 645-658. DOI: 10.1016/j.healun.2024.11.021.

[63] RAHMAN M, SCOZZI D, EGUCHI N, et al. Downregulation of tumor suppressor gene LKB1 during severe primary graft dysfunction after human lung transplantation: implication for the development of chronic lung allograft dysfunction[J]. Transplantation, 2025, 109(3): 476-483. DOI: 10.1097/TP.0000000000005172.

[64] MELLORS P W, LANGE A N, CASINO REMONDO B, et al. Shared roles of immune and stromal cells in the pathogenesis of human bronchiolitis obliterans syndrome[J]. JCI Insight, 2025, 10(10): e176596. DOI: 10.1172/jci.insight.176596.

[65] MINEURA K, TANAKA S, GODA Y, et al. The effect of CTLA4-Ig on fibrotic progression in a murine model of chronic lung allograft dysfunction[J]. J Heart Lung Transplant, 2025, 44(9): 1504-1509. DOI: 10.1016/j.healun.2025.05.002.

[66] MOGHBELI K, LIPP M A, BUENO M, et al. NKG2D blockade impairs tissue-resident memory T cell accumulation and reduces chronic lung allograft dysfunction[J]. JCI Insight, 2025, 10(4): e184048. DOI: 10.1172/jci.insight.184048.

[67] WAN L, WU Y, YANG J, et al. The mechanosensitive ion channel Piezo1 promotes obliterative bronchiolitis through YAP-dependent epithelial-to-mesenchymal transition[J]. Curr Mol Med, 2025, DOI: 10.2174/0115665240377965250701114255 [Epub ahead of print].

[68] CENIK I, VAN SLAMBROUCK J, BARBAROSSA A, et al. Temperature dynamics of porcine and human lungs during static ice storage: ice is not 4 ℃[J]. J Clin Med, 2025, 14(6): 2127. DOI: 10.3390/jcm14062127.

[69] HILL M A, TENNANT M, WATTS B, et al. Evaluation of ventilation at 10 ℃ as the optimal storage condition for donor lungs in a murine model[J]. Sci Rep, 2026, 16: 7228. DOI: 10.1038/s41598-026-35943-2.

[70] WANG A, ALI A, BACIU C, et al. Metabolomic studies reveal an organ-protective hibernation state in donor lungs preserved at 10 ℃[J]. J Thorac Cardiovasc Surg, 2025, 169(3): 796-810. e1. DOI: 10.1016/j.jtcvs.2024.08.015.

[71] YAMANASHI K, WANG A, BELLISSIMO C A, et al. Protective effects of 10 ℃ preservation on donor lungs with lipopolysaccharide-induced acute lung injury[J]. J Thorac Cardiovasc Surg, 2025, 169(6): e74-e87. DOI: 10.1016/j.jtcvs.2024.09.022.

[72] UJIKE H, TANAKA S, MATSUBARA K, et al. Combined inflation and cooling method improves lung function in uncontrolled donation after circulatory death[J]. J Thorac Cardiovasc Surg, 2026, 171(1): 61-72. e3. DOI: 10.1016/j.jtcvs.2025.08.034.

[73] TIAN D, WANG Y, SHIIYA H, et al. Outcomes of marginal donors for lung transplantation after ex vivo lung perfusion: a systematic review and meta-analysis[J]. J Thorac Cardiovasc Surg, 2020, 159(2): 720-730. e6. DOI: 10.1016/j.jtcvs.2019.07.087.

[74] FAROOQUI A, CHAN C H H, TAN C, et al. Effect of blood-air contact on blood-based perfusates for ex vivo lung perfusion using an in vitro approach^* [C]// 2025 47th Annual International Conference of the IEEE Engineering in Medicine and Biology Society (EMBC). Copenhagen, Denmark. IEEE, 2025: 1-5. DOI: 10.1109/embc58623.2025.11251574.

[75] DEBONNEVILLE A, PARAPANOV R, ALLOUCHE M, et al. Thermal preconditioning during ex-vivo lung perfusion for the rehabilitation of damaged lung grafts before transplantation[J]. JoVE, 2025(224). DOI: 10.3791/69084.

[76] PARAPANOV R, DEBONNEVILLE A, ALLOUCHE M, et al. Optimal duration of ex vivo lung perfusion for heat stress-mediated therapeutic reconditioning of damaged rat donor lungs[J]. Eur J Cardio Thorac Surg, 2025, 67(2): ezaf027. DOI: 10.1093/ejcts/ezaf027.

[77] KRISHNAN A, FAWAD M, ELDE S, et al. Preservation of bronchial artery circulation on ex-vivo lung perfusion[J]. Sci Rep, 2025, 15(1): 23354. DOI: 10.1038/s41598-025-06174-8.

[78] NODA K, ATALE N, AUSTIN T, et al. Hepatic conditioning results in better lung endothelial cell preservation under hypoxic environment in vitro[J]. Int J Artif Organs, 2025, 48(2): 84-91. DOI: 10.1177/03913988251315092.

[79] ZHANG J, ZHANG X, HE J. An optimized perfusate for enhanced rat ex vivo lung perfusion and lung transplant models[J]. Anim Models Exp Med, 2025, 8(8): 1532-1536. DOI: 10.1002/ame2.70004.

[80] FAIZOV L, ZUPAROV Y, TURAROVA A, et al. Enhanced donor lung viability during prolonged ex vivo lung perfusion using ECMO technology[J]. Transpl Int, 2025, 38: 14284. DOI: 10.3389/ti.2025.14284.

[81] TANAKA S, UMEDA M, UJIKE H, et al. Novel pulmonary abdominal normothermic regional perfusion circuit for simultaneous in-donor evaluation and preservation of lungs and abdominal organs in donation after circulatory death[J]. Gen Thorac Cardiovasc Surg, 2025, 73(9): 700-708. DOI: 10.1007/s11748-025-02137-y.

[82] DEMAREST C T, ZOFKIE B Z, POPA S, et al. Impact of normothermic regional perfusion on ex vivo lung perfusion outcomes in donation after circulatory death lung donors[J]. J Thorac Cardiovasc Surg, 2026, 171(3): 792-800. e2. DOI: 10.1016/j.jtcvs.2025.10.014.

[83] VANDENDRIESSCHE K, ORLITOVÁ M, VANSTAPEL A, et al. Preclinical research on the effect of thoraco-abdominal normothermic regional perfusion on pulmonary function: a comparison of 2 strategies[J]. Am J Transplant, 2025, 25(12): 2554-2564. DOI: 10.1016/j.ajt.2025.07.2485.

[84] TRACY K M, HARRIS T R, PETROVIC M, et al. Lung rehabilitation using xenogeneic cross-circulation does not lead to hyperacute rejection in a human lung transplantation model[J]. J Heart Lung Transplant, 2025, 44(7): 1122-1134. DOI: 10.1016/j.healun.2025.02.1696.

[85] YOKOYAMA Y, TOYOMOTO M, TANAKA N, et al. The novel compound PICCS improves cell viability during cold storage and reduces pulmonary ischemia-reperfusion injury in a rat model[J]. Sci Rep, 2025, 15(1): 15217. DOI: 10.1038/s41598-025-99851-7.

[86] YAMAMOTO H, WILSON G W, SUNDBY A, et al. Cell-free DNA in ex-vivo lung perfusate is associated with low-quality lungs and lung transplant outcome[J]. J Heart Lung Transplant, 2025, 44(9): 1438-1448. DOI: 10.1016/j.healun.2025.02.1693.

[87] YAMAMOTO H, ALLEN J, SUNDBY A, et al. Rapid donor-specific single nucleotide variation detection by nanopore sequencing of ex vivo lung perfusate[J]. JHLT Open, 2026, 11: 100433. DOI: 10.1016/j.jhlto.2025.100433.

[88] ZHAO Y, LIANG L, MCCAIG A, et al. Activation of PANoptosis and ferroptosis during ex vivo lung perfusion in human lungs[J]. J Heart Lung Transplant, 2025, 44(9): 1469-1481. DOI: 10.1016/j.healun.2025.04.003.

[89] VERMA H K, GERCKENS M, CONLON T M, et al. Cystatin C prevents tissue injury after lung transplantation[J]. Life Sci Alliance, 2026, 9(2): e202503312. DOI: 10.26508/lsa.202503312.

[90] MIYAMOTO E, OHSUMI A, HWANG D, et al. Ex vivo lung perfusion-to-lung transplant rat survival model with reproducible development of acute lung injury and graft rejection[J]. JHLT Open, 2025, 9: 100299. DOI: 10.1016/j.jhlto.2025.100299.

[91] SAHIN M F, ESENDAGLｌ G, YｌLDｌRｌM F, et al. Refined cuff technique minimizes surgical complexity in rat lung transplantation and improves outcomes[J]. Sci Rep, 2025, 15(1): 35876. DOI: 10.1038/s41598-025-19711-2.

[92] WU Y, ZHANG X, LI Y, et al. A novel approach to establish orthotopic right lung transplantation in rats[J]. JHLT Open, 2025, 10: 100407. DOI: 10.1016/j.jhlto.2025.100407.

基金资助

国家自然科学基金面上项目(82470104)

四川省医学会科研项目(S20250043)

四川省医学科技创新研究会项目(YCH-KY-YCZD2024-227)